

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Medtide Inc.

泰德醫藥(浙江)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3880)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Medtide Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purposes of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication, considering the recommendation on the payment of a final dividend, if any, and transacting any other business.

By order of the Board

Medtide Inc.

泰德醫藥(浙江)股份有限公司

Dr. Xu Qi

Chairwoman and Chief Executive Officer

Hong Kong, March 16, 2026

As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉), Ms. Cheng Tao and Ms. Li Lingmei (李玲梅); the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).